Analgesics in Middle East and Africa

October 2020

Analgesics in the Middle East and Africa faces challenges against the backdrop economic slowdown. Self-medication, generics and product innovation have positively influenced demand, but lower consumer confidence and economic turmoil in key markets have had a negative impact. Growth potential remains high, with typically low per capita usage across the region, but the onset of COVID-19 can be expected to intensify and exacerbate economic problems.

USD 1,475
Request More Information

Delivery

This report comes in PPT.

Key findings

Self-medication and increasing product awareness driving growth across the region

The Middle East and Africa is increasingly characterised by rising product awareness, with a widening availability of brands across price points and quality. Consumers are increasingly stocking up on analgesics for relief of common ailments. Well-trusted brands such as Panadol have done much to raise awareness of analgesics for pain relief and the treatment of flu-related symptoms.

Public health systems encourage growth

African countries such as Egypt and South Africa can suffer from overburdened public health systems, which is further fuelling the trend towards self-medication.

Economic problems in the Middle East

High value markets in the Middle East, such as Saudi Arabia and the United Arab Emirates face real economic challenges, such as falling oil prices, and government-led initiatives resulting in the departure of expatriates from both countries. COVID-19 has also cast a dark shadow over economic prospects; tourism, for example, has been hit hard in 2020.

Affordability key to growth in developing markets

Developing economies in the African and Sub-Saharan region are benefiting from increased usage of inexpensive analgesic brands, such as Adcock Ingram’s Panado in South Africa.

High growth for topical analgesics

Topical analgesics is expected to witness 6% forecast CAGR versus 3.5% in systemic analgesics, as consumers start to balance usage among the two, partially due to rising awareness of side effects of frequent long-term usage of oral analgesics. Systemic analgesics will still dominate in terms of actual US dollar value gains, however.

Scope
Key findings
Putting Middle East and Africa in context
Analgesics a staple pain relief, but economic impact leaves its mark on sales
Middle East and Africa benefits from having youngest population globally
Consumer preference for analgesics as the first line of treatment
Systemic analgesics dominate but topical analgesics also popular
Lifestyle diseases fuel growth for systemic analgesics
High gains for systemic analgesics in Egypt; decline in Saudi Arabia
Self-medication trend driven by convenience
74% of total regional sales made in chemists/pharmacies
Chained pharmacies first to venture into omnichannel approach
Five top ranked companies drive majority of sales across the region
GSK dominates with its first line pain relievers Panadol and Voltaren
Generic brands gain traction
Panadol and Voltaren lead
Strongest gains predicted for Egypt
Mixed prospects ahead
Algeria: Competitive and Retail Landscape
Algeria: Market Context
Cameroon: Market Context
Cameroon: Competitive and Retail Landscape
Egypt: Market Context
Egypt: Competitive and Retail Landscape
Israel: Market Context
Israel: Competitive and Retail Landscape
Kenya: Market Context
Kenya: Competitive and Retail Landscape
Morocco: Market Context
Morocco: Competitive and Retail Landscape
Nigeria: Market Context
Nigeria: Competitive and Retail Landscape
Saudi Arabia: Market Context
Saudi Arabia: Competitive and Retail Landscape
South Africa: Market Context
South Africa: Competitive and Retail Landscape
Tunisia: Market Context
Tunisia: Competitive and Retail Landscape
United Arab Emirates: Market Context
United Arab Emirates: Competitive and Retail Landscape

Consumer Health

It is the aggregation of OTC, Vitamins and Dietary Supplements (VDS), Sports Nutrition, and Weight Management and Wellbeing

See All of Our Definitions
Share:

NEW REPORT GUARANTEE

If you purchase a report that is updated in the next 60 days, we will send you the new edition and data extraction Free!

;